66955-76-8

Usage

Uses

Used in Pharmaceutical Industry:
Diclofenac is utilized as an analgesic and anti-inflammatory agent for the treatment of various conditions. It is particularly effective against arthritis, migraines, and menstrual cramps. The drug can be administered through different methods, including oral and topical application, and is available in a range of forms such as tablets, capsules, and gels.
Used in Pain Management:
Diclofenac serves as a pain reliever, helping to mitigate discomfort associated with different medical conditions. Its anti-inflammatory properties also contribute to its efficacy in managing pain.
Used in Inflammation Reduction:
Beyond pain relief, diclofenac is also used to reduce inflammation. This application is beneficial in treating conditions characterized by inflammation, such as certain types of arthritis.
It is crucial to follow the guidance of healthcare professionals when using diclofenac to minimize the risk of side effects, which may include stomach upset, heartburn, and dizziness.

Upstream product

• 1258845-93-0 (4-amino-3,5-dichlorophenyl)acetic acid ethyl ester 

Downstream Products

• 1258845-87-2 2-(4-tert-butylbenzyl)-3-[2-(4-amino-3,5-dichlorophenyl)acetamido]propyl pivalate 
• 1092504-43-2 C₃₅H₄₁Cl₂N₇O₃ 
• 1092504-36-3 C₃₄H₄₀Cl₂N₆O₂ 
• 1092504-72-7 C₁₄H₁₅Cl₂N₃O₂*ClH 
• 1092504-71-6 C₁₃H₁₇Cl₂N₃O*ClH 
• 1092504-66-9 C₁₃H₁₄Cl₂N₂O*ClH 
• 1092067-93-0 C₃₃H₃₈Cl₂N₆O₄ 
• 1092069-63-0 C₁₃H₁₄Cl₂N₂O 
• 1092170-36-9 C₁₂H₁₆Cl₂N₂ 
• 1092069-69-6 C₁₄H₁₅Cl₂N₃O₂ 
• 1092069-62-9 C₁₂H₁₆Cl₂N₂*ClH 
• 1092069-68-5 C₁₃H₁₇Cl₂N₃O 
• 1092069-61-8 C₁₂H₁₄Cl₂N₂O 

Relevant academic research and scientific papers

Halogenation of 4-hydroxy/amino-3-methoxyphenyl acetamide TRPV1 agonists showed enhanced antagonism to capsaicin

As an extension of our analysis of the effect of halogenation on thiourea TRPV1 agonists, we have now modified selected 4-hydroxy(or 4-amino)-3- methoxyphenyl acetamide TRPV1 agonists by 5- or 6-halogenation on the aromatic A-region and evaluated them for potency for TRPV1 binding and regulation and for their pattern of agonism/antagonism (efficacy). Halogenation shifted the functional activity at TRPV1 toward antagonism with a greater extent of antagonism as the size of the halogen increased (I > Br > Cl), as previously observed for the thiourea series. The extent of antagonism was greater for halogenation at the 5-position than at the 6-position, in contrast to SAR for the thiourea series. In this series, compounds 55 and 75 showed the most potent antagonism, with Ki (ant) = 2.77 and 2.19 nM, respectively, on rTRPV1 expressed in Chinese hamster ovary cells. The compounds were thus ca. 40-60-fold more potent than 6′-iodononivamide.

Pyrazol-1-ylphenylacetic acids

Pyrazol-1-ylphenylacetic acids of the formula STR1 wherein R1, R2 and R3 are the same or different and denote a hydrogen atom or a halogen atom, R4 denotes a hydrogen atom or an alkyl group, A B denotes a carbon-carbon single or double bond, and their salts are pharmacologically active and are useful as medicaments. Medicament compositions are produced therefrom. Their functional carboxylic acid derivatives and other new intermediates are used in their preparation.